DrugPatentWatch Database Preview

Details for Patent: 9,358,207

« Back to Dashboard

Which drugs does patent 9,358,207 protect, and when does it expire?

Patent 9,358,207 protects ABILIFY and is included in one NDA.

This patent has seventy-four patent family members in forty-six countries.

Summary for Patent: 9,358,207

Title:	Flashmelt oral dosage formulation
Abstract:	There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
Inventor(s):	Kothari; Sanjeev H. (Princeton, NJ), Desai; Divyakant S. (West Windsor, NJ)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	13/938,706
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,358,207

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Otsuka	ABILIFY	aripiprazole	TABLET, ORALLY DISINTEGRATING;ORAL	021729-002	Jun 7, 2006		DISCN	No	No			Y
Otsuka	ABILIFY	aripiprazole	TABLET, ORALLY DISINTEGRATING;ORAL	021729-003	Jun 7, 2006		DISCN	No	No			Y
Otsuka	ABILIFY	aripiprazole	TABLET, ORALLY DISINTEGRATING;ORAL	021729-004	Jun 7, 2006		DISCN	Yes	No			Y
Otsuka	ABILIFY	aripiprazole	TABLET, ORALLY DISINTEGRATING;ORAL	021729-005	Jun 7, 2006		DISCN	Yes	No			Y

Non-Orange Book US Patents Family Members for Patent 9,358,207

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,518,421	Flashmelt oral dosage formulation

International Patents Family Members for US Patent 9,358,207

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	024384
Argentina	036658
Argentina	098808
Austria	328584